Phathom Pharmaceuticals earnings date
Want to see PHAT full AI Analyst Report?
Phathom Pharmaceuticals (PHAT) Q3 2026 Earnings Report
PHAT Q3 2026 EPS Results
- Actual EPS
- -$0.16
- Consensus EPS
- -$0.12
- Beat/Miss
- Missed by -$0.04
- One Year Ago EPS
- -$0.41
PHAT Q3 2026 Revenue Results
- Actual Revenue
- $84.72M
- Expected Revenue
- $84.82M
- Beat/Miss
- Missed by -$100.00K
- YoY Revenue Growth
- +71.14%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 10/29/2026
- Time
- Before Open
- Conference Call
- Thursday, October 29, 2026
Phathom Pharmaceuticals's next earnings date is estimated for March 2, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was strongly positive, supported by 71% year-over-year revenue growth, 14% sequential growth, a second consecutive quarter of operating profitability, positive operating cash flow, more than two million prescriptions filled, reaffirmed full-year guidance, and a substantial cash balance. The main challenges were a Q3 gross margin miss, expected higher Q4 gross-to-net discount, gradual access adoption, and litigation concerning VOQUEZNA's exclusivity, but management remained confident in the commercial trajectory, cash outlook, development pipeline, and long-term GI strategy.
Phathom reiterated full-year 2026 revenue guidance of $310 million-$325 million, expects its full year 2026 gross-to-net discount to come in towards the lower part of its 55%-59% guidance range, continues to anticipate gross margin will be approximately 80%, and maintained cash operating expense guidance, excluding stock-based compensation, of $235 million-$245 million, tracking towards the lower part of that range; it also expects its second consecutive quarter of operating profitability to represent a sustainable pattern going into Q4, including in total for full year 2026 and beyond, and maintained guidance of reaching durable positive cash flow in 2027.
- Strong Q3 Revenue Growth and ProfitabilityQ3 net revenue was $84.7 million, up approximately 71% year over year and 14% sequentially. The company delivered its second consecutive quarter of positive operating profit excluding stock-based compensation, with positive operating profit of $5.8 million, and generated approximately $2.1 million of cash from operations.
- Full-Year 2026 Guidance ReaffirmedPhathom maintained full-year 2026 revenue guidance of $310 million-$325 million, cash operating expense guidance of $235 million-$245 million excluding stock-based compensation, and gross margin guidance of approximately 80%. Management said it is tracking toward the lower part of the cash operating expense range and expects gross-to-net discount to be toward the lower part of the 55%-59% guidance range.
- Growing VOQUEZNA Prescription BaseMore than two million VOQUEZNA prescriptions had been filled since launch through October 16, 2026. Approximately 380,000 prescriptions were filled in Q3, including about 248,000 covered prescriptions, representing approximately 65% of the total, and about 132,000 cash-pay prescriptions. Covered volume increased 19% sequentially, while cash volume increased 6%.
- Positive Physician Perception of EfficacyIn recent market research, 97% of surveyed healthcare professionals rated VOQUEZNA's efficacy favorably compared with other GERD treatment options. Management said physicians are already convinced of the product's clinical value.
- Broad Commercial Payer CoverageManagement reported that more than 80% of commercial lives have coverage for VOQUEZNA and described the product's market access coverage as solid and broad-based.
- Access First Initiatives Showing Early ProgressPhathom shifted its sales force toward Access First initiatives focused on prior authorization education, BlinkRx support, and patient support programs. Management said it is seeing positive early signals, including more new-to-brand prescriptions being routed to BlinkRx.
- BlinkRx Improving Prescription FulfillmentManagement stated that prescriptions sent to BlinkRx have higher prior authorization submission and approval rates and significantly higher overall total prescription fill rates than prescriptions sent to retail pharmacies. BlinkRx also supports prior authorization navigation, patient communication, automatic application of eligible support programs, and access to lower out-of-pocket costs.
- $0 Copay Program Expands Patient AccessAt the end of Q3, Phathom introduced a $0 copay offering through BlinkRx for eligible commercially insured patients whose plans cover VOQUEZNA, excluding Massachusetts because of state restrictions. The company said the program is intended to improve affordability perceptions and encourage greater BlinkRx adoption. Management characterized the incremental gross-to-net impact as minor or insignificant and said incremental prescription contribution should more than offset the additional support cost.
- Strong Cash Position and Covenant HeadroomPhathom ended Q3 with $184.6 million in cash and cash equivalents. Beginning October 1, 2026, the cash holding requirement under the Revenue Interest Financing Agreement was approximately $119 million, leaving the company with cash materially above the requirement. Management said current cash and anticipated future operating cash flow should be sufficient to invest in the business and satisfy covenants without another debt or equity raise.
- Positive Cash Flow OutlookManagement maintained its guidance to reach durable positive cash flow in 2027 and said it expects revenue to grow faster than operating expenses, creating operating leverage. The company also said the second consecutive quarter of operating profitability represents a sustainable pattern going into Q4, full-year 2026, and beyond.
- EoE Development Program Nears Initial Data ReadoutPhathom expects to report top-line data in Q4 from the phase II pHalcon-EoE trial. The primary endpoint is histologic improvement, measured by a reduction in eosinophil counts after 12 weeks, with symptom improvement evaluated as a secondary endpoint. The additional 12-week open-label safety extension is ongoing, with the full 24-week data expected toward the latter part of Q1.
- Potential Pediatric Exclusivity OpportunityManagement said the EoE study is intended to support a potential exclusivity extension in addition to expanding VOQUEZNA use into EoE. If the study is successful and subsequent discussions with the FDA support a written request for pediatric studies, completing the study could qualify Phathom for a six-month pediatric exclusivity extension.
- As-Needed NERD Study ProgressingThe phase III pHalcon-NERD-302 study of VOQUEZNA for as-needed treatment of non-erosive GERD is enrolling patients. The study includes four weeks of daily treatment followed by six months of randomized as-needed VOQUEZNA or placebo treatment, with top-line data expected in Q1 2028.
- VOQUEZNA Exclusivity Recognized Through May 3, 2032Management reiterated that the FDA recognized 10 years of NCE exclusivity, as extended by the GAIN Act, for products containing vonoprazan. The FDA updated the Orange Book to recognize exclusivity for VOQUEZNA tablets through May 3, 2032, and Phathom said it intends to vigorously defend its statutory exclusivities.
- Payer Negotiations Unchanged by Potential Second PCABManagement said it has not seen any meaningful change in commercial payer negotiations or access based on the potential introduction of a second PCAB. The company also expects a second PCAB sales force to increase awareness of the PCAB category and potentially create a tailwind for the market-leading VOQUEZNA.
- GI-Focused Commercial Strategy and Future Portfolio ExpansionPhathom said more than 70% of sales calls are directed to gastroenterologists and that GI will remain the core commercial focus through 2027. Management intends to build a broader GI business, with potential future deals involving commercial products or phase II programs that could be launched before potential exclusivity loss in 2033.
PHAT Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 02, 2027 | 2026 (Q4) | -0.09- | -0.29 | ― | ― |
| Oct 29, 2026 | 2026 (Q3) | -0.12-0.16 | -0.41 | 60.98% (+0.25) | |
| Jul 30, 2026 | 2026 (Q2) | -0.18-0.21 | -1.05 | 80.00% (+0.84) | |
| Apr 30, 2026 | 2026 (Q1) | -0.29-0.37 | -1.31 | 71.76% (+0.94) | |
| Feb 26, 2026 | 2025 (Q4) | -0.41-0.29 | -1.05 | 72.38% (+0.76) | |
| Oct 30, 2025 | 2025 (Q3) | -0.46-0.41 | -1.32 | 68.94% (+0.91) | |
| Aug 07, 2025 | 2025 (Q2) | -0.95-1.05 | -1.56 | 32.69% (+0.51) | |
| May 01, 2025 | 2025 (Q1) | -1.10-1.31 | -1.42 | 7.75% (+0.11) | |
| Mar 06, 2025 | 2024 (Q4) | -1.22-1.05 | -1.39 | 24.46% (+0.34) | |
| Nov 07, 2024 | 2024 (Q3) | -1.47-1.32 | -0.76 | -73.68% (-0.56) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


